1. Home
  2. ATEC vs XERS Comparison

ATEC vs XERS Comparison

Compare ATEC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alphatec Holdings Inc.

ATEC

Alphatec Holdings Inc.

HOLD

Current Price

$8.32

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.34

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEC
XERS
Founded
1990
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
ATEC
XERS
Price
$8.32
$8.34
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
$22.00
$10.83
AVG Volume (30 Days)
2.6M
2.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
15.04
100.00
EPS
N/A
0.01
Revenue
$101,739,000.00
$49,590,000.00
Revenue This Year
$18.97
$34.37
Revenue Next Year
$16.70
$22.86
P/E Ratio
N/A
$841.00
Revenue Growth
N/A
142.67
52 Week Low
$6.82
$4.87
52 Week High
$23.29
$10.08

Technical Indicators

Market Signals
Indicator
ATEC
XERS
Relative Strength Index (RSI) 42.68 56.23
Support Level $8.10 $8.00
Resistance Level $8.42 $8.42
Average True Range (ATR) 0.38 0.37
MACD -0.14 -0.08
Stochastic Oscillator 12.95 30.39

Price Performance

Historical Comparison
ATEC
XERS

About ATEC Alphatec Holdings Inc.

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: